Hologic Announces Financial Results for Second Quarter of Fiscal 2021

Rhea-AI Summary

Hologic, Inc. (HOLX) reported its fiscal Q2 results, with revenues soaring 103.4% to $1.54 billion and EPS surging 561.1% to $2.38. This growth was fueled by a 390.6% increase in molecular diagnostics revenue, reaching $935.3 million, driven by strong demand for COVID-19 testing. The company completed acquisitions worth over $1 billion, aiming to enhance post-pandemic growth. Operating margin expanded to 51.8%, while cash flow from operations was $552.3 million. Despite strong results, future COVID testing revenue may be conservative, impacting Q3 guidance.

Positive

• Revenue increased 103.4% to $1.54 billion.
• EPS surged 561.1% to $2.38.
• Molecular diagnostics revenue jumped 390.6% to $935.3 million.
• Operating margin improved to 51.8%.
• Strong cash flow from operations of $552.3 million.
• Completed three acquisitions totaling over $1 billion.

Negative

• Future COVID testing revenue outlook may be conservative.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 27, 2021.

“Hologic posted very strong financial results in our second fiscal quarter in line with our guidance,” said Steve MacMillan, the Company’s chairman, president and chief executive officer. “Organic revenue doubled, driven by strong recovery and momentum in our base businesses, as well as our continued response to the COVID-19 pandemic. And earnings per share more than quadrupled. We also used our strong cash flows to complete three acquisitions and announce another, which we believe will accelerate our growth and make us a stronger company post-pandemic.”

Recent Highlights

• Revenue increased 103.4% for the quarter, or 98.7% in constant currency. Excluding material acquisitions and divestitures, organic revenue in the second quarter increased 104.7%, or 100.0% in constant currency.
• Worldwide molecular diagnostics revenue of $935.3 million increased 390.6%, or 378.4% in constant currency, based on strong global demand for the Company’s two SARS-CoV-2 assays that run on the fully automated Panther® and Panther Fusion® systems.
• On April 8, announced an agreement to acquire Mobidiag, a Finnish, commercial-stage developer of molecular diagnostic tests and instrumentation, for an enterprise value of approximately $795 million.
• On March 1, completed the acquisition of Diagenode, a Belgian developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $153 million.
• On February 22, completed the acquisition of Biotheranostics, a commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $232 million. Biotheranostics’ Breast Cancer Index test was recently added to the National Comprehensive Cancer Network’s guidelines to predict the benefit from extended endocrine therapy.
• On December 30, completed the acquisition of SOMATEX, a German leader in biopsy site markers and localization technologies, for approximately $63 million.
• Cash flow from operations was $552.3 million in the second quarter. In addition to the acquisitions discussed above, the Company used its strong cash flow to repurchase 1.6 million shares of its common stock for $120 million in the second quarter.

Key financial results for the fiscal second quarter are shown in the table below.

	GAAP				Non-GAAP
	Q2’21	Q2’20	Change Increase (Decrease)		Q2’21	Q2’20	Change Increase (Decrease)
Revenues	$1,537.6	$756.1	103.4%		$1,537.6	$756.1	103.4%
Gross Margin	70.6%	52.3%	1,830 bps		75.0%	61.0%	1,400 bps
Operating Expenses	$289.0	$239.4	20.7%		$277.7	$222.5	24.8%
Operating Margin	51.8%	20.7%	3,110 bps		56.9%	31.5%	2,540 bps
Net Margin	40.3%	12.5%	2,780 bps		43.8%	20.0%	2,380 bps
Diluted EPS	$2.38	$0.36	561.1%		$2.59	$0.57	354.4%

Throughout this press release, all dollar figures are in millions, except EPS, unless otherwise noted. Some totals may not foot due to rounding. Unless otherwise noted, all results are compared to the corresponding prior year period. Non-GAAP results exclude certain cash and non-cash items as discussed under “Use of Non-GAAP Financial Measures.” Constant currency percentage changes show current period revenue results as if the foreign exchange rates were the same as those in the prior year period. Organic revenue is on a constant currency basis and excludes the divested Blood Screening business, as well as the acquired Acessa, Biotheranostics and Diagenode businesses.

Revenue Detail

				Increase (Decrease)
$ in millions	Q2’21		Q2’20	Global Reported Change	Global Constant Currency Change	U.S. Reported Change	International Reported Change	International Constant Currency Change
Diagnostics
Cytology & Perinatal	$117.2		$113.4	3.3%	0.7%	4.9%	0.5%	(6.8%)
Molecular Diagnostics	$935.3		$190.6	390.6%	378.4%	311.4%	681.8%	624.3%
Blood Screening	$12.0		$15.2	(21.3%)	(21.3%)	(21.3%)	N/A	N/A
Total Diagnostics	$1,064.5		$319.2	233.4%	225.2%	195.9%	343.8%	311.2%
Excluding Blood	$1,052.5		$304.0	246.2%	237.5%	210.8%	343.8%	311.2%
Breast Health
Breast Imaging	$269.9		$250.2	7.9%	5.8%	6.4%	12.0%	3.8%
Interventional Breast Solutions	$66.4		$57.6	15.4%	13.9%	13.6%	24.8%	15.6%
Total Breast Health	$336.3		$307.8	9.3%	7.3%	7.9%	13.6%	5.3%
GYN Surgical	$114.2		$105.4	8.4%	6.6%	5.9%	20.2%	10.1%
Skeletal Health	$22.6		$23.7	(4.8%)	(6.8%)	(9.7%)	4.7%	(1.1%)
Total	$1,537.6		$756.1	103.4%	98.7%	85.1%	161.4%	142.2%
Excluding divested Blood business and Acessa, Biotheranostics and Diagenode acquisitions (organic)	$1,516.4		$740.9	104.7%	100.0%	86.8%	159.9%	140.7%

Other Financial Highlights

• U.S. revenue of $1,064.0 million increased 85.1%. International revenue of $473.6 million increased 161.4%, or 142.2% in constant currency. Organically, U.S. revenue of $1,045.5 million increased 86.8%, while international revenue of $470.9 million increased 159.9%, or 140.7% in constant currency.
• GAAP gross margin of 70.6% increased 1,830 basis points. Non-GAAP gross margin of 75.0% increased 1,400 basis points, primarily due to sales of the Company’s SARS-COV-2 tests.
• GAAP operating margin of 51.8% increased 3,110 basis points. Non-GAAP operating margin of 56.9% increased 2,540 basis points, primarily due to sales of the Company’s SARS-COV-2 tests.
• GAAP net income attributable to Hologic of $619.9 million increased 543.7%. Non-GAAP net income attributable to Hologic of $674.1 million increased 346.7%. Adjusted non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) was $896.7 million, an increase of 261.1%.
• Total principal debt outstanding at the end of the second quarter was $2.78 billion. The Company ended the quarter with cash and equivalents of $816.4 million, and a net leverage ratio (net debt over adjusted EBITDA) of 0.7 times.
• On a trailing 12 months basis, adjusted Return on Invested Capital (ROIC) of 33.4% increased 2,090 basis points compared to the prior year period.

Financial Guidance for the Third Quarter of Fiscal 2021

“We forecast strong financial results in our third fiscal quarter, driven by continued strength and recovery in our base businesses, partially offset by a potentially conservative but still significant outlook for COVID test revenue given the rapidly evolving market dynamics,” said Karleen Oberton, Hologic’s chief financial officer.

Hologic’s financial guidance for the third quarter of fiscal 2021 is shown in the table below. The guidance is based on a non-GAAP tax rate of approximately 21.5%, and 261 million diluted shares outstanding for the quarter. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2021 as in fiscal 2020. Current guidance assumes that recent foreign exchange rates persist for all of the third quarter of fiscal 2021. Organic revenue guidance is on a constant currency basis and excludes the divested Blood Screening and the acquired Acessa, Biotheranostics, and Diagenode businesses. The guidance does not include the impact of the pending Mobidiag acquisition, which is expected to close early in the fourth quarter of fiscal 2021.

		Guidance for the Third Quarter of Fiscal 2021
		Guidance $		Reported % Increase (Decrease)		Constant Currency % Increase (Decrease)		Organic % Increase (Decrease)
Q3 2021
Revenue		$1,000 - $1,070		21.5% to 30.0%		17.9% to 26.4%		15.1% to 23.6%
GAAP EPS		$0.74 - $0.89		39.6% to 67.9%
Non-GAAP EPS		$1.00 - $1.15		33.3% to 53.3%

Use of Non-GAAP Financial Measures

The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; and adjusted EBITDA. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures to exclude, as applicable: (i) the amortization of intangible assets and impairment of goodwill, intangible assets and equipment; (ii) adjustments to record contingent consideration at fair value; (iii) additional expenses resulting from the purchase accounting adjustment to record inventory at fair value; (iv) restructuring and divestiture charges and facility closure and consolidation charges, including accelerated depreciation, and costs incurred to integrate acquisitions (including retention, transaction bonuses, legal and professional consulting services) and separate divested businesses from existing operations; (v) expenses related to the divested Cynosure business incurred subsequent to the disposition date primarily related to indemnification provisions for legal and tax matters; (vi) transaction related expenses for divestitures and acquisitions; (vii) third-party expenses incurred related to implementing the European MDR/IVDR requirements and obtaining the appropriate approvals for its existing products; (viii) debt extinguishment losses and related transaction costs; (ix) the unrealized (gains) losses on the mark-to-market of forward foreign currency contracts and foreign currency option contracts for which the Company has not elected hedge accounting; (x) litigation settlement charges (benefits) and non-income tax related charges (benefits); (xi) other-than-temporary impairment losses on investments and realized gains and losses resulting from the sale of investments; (xii) the one-time discrete impacts related to internal restructuring and non-operational items; (xiii) other one-time, non-recurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (xiv) income taxes related to such adjustments. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines organic revenue to exclude the divested Blood Screening, and the acquired Acessa, Biotheranostics, and Diagenode businesses.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company's definition of these non-GAAP measures may differ from similarly titled measures used by others.

The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of Hologic's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Hologic's business.

Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Conference Call and Webcast

Hologic’s management will host a conference call at 4:30 p.m. ET today to discuss its financial results for the second quarter of fiscal 2021. Approximately 10 minutes before the call, dial 800-263-0877 (in the United States and Canada) or +1 323-794-2094 (for international callers) and enter access code 7731175. A replay will be available approximately two hours after the call ends through Friday, May 21, 2021. The replay numbers are 888-203-1112 (U.S.) or +1 719-457-0820 (international), access code 7731175, PIN 5337. The Company will also provide a live webcast of the call at investors.hologic.com.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company’s strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the severity and duration of the COVID-19 pandemic and its impact on the U.S. healthcare system, the U.S. economy and worldwide economy; the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic; continued demand for the Company’s COVID-19 TMA assay; the Company’s ability to manufacture, on a scale necessary to meet demand, its COVID-19 TMA assay as well as the Panther systems on which the assay runs; U.S., European and general worldwide economic conditions, trade relations, and related uncertainties; manufacturing risks, including the Company’s reliance on a single or limited source of supply for key components, the need to comply with especially high standards for the manufacture of many of its products and risks associated with utilizing third party manufacturers; the Company’s ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the ability of the Company to successfully manage leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; the Company’s reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; changes to applicable laws and regulations, including tax laws, global health care reform, and import/export trade laws; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company’s products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including, without limitation, the Company’s ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company’s international activities and businesses; the early stage of market development for certain of the Company’s products; the Company’s leverage risks, including the Company’s obligation to meet payment obligations and financial covenants associated with its debt; cybersecurity risks; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

SOURCE: Hologic, Inc.

HOLOGIC, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In millions, except number of shares, which are reflected in thousands, and per share data)
	Three Months Ended								Six Months Ended
	March 27, 2021				March 28, 2020				March 27, 2021				March 28, 2020
Revenues:
Product	$	1,378.8			$	623.6			$	2,834.2			$	1,322.9
Service and other	158.8				132.5				313.2				283.7
Total revenues	1,537.6				756.1				3,147.4				1,606.6
Cost of revenues:
Product	300.7				223.3				585.2				460.8
Amortization of acquired intangible assets	64.5				62.9				126.1				126.5
Impairment of intangible assets and equipment	—				—				—				25.8
Service and other	86.6				74.1				170.0				163.9
Gross profit	1,085.8				395.8				2,266.1				829.6
Operating expenses:
Research and development	71.5				49.3				130.7				110.4
Selling and marketing	131.5				110.6				259.5				255.4
General and administrative	88.9				67.0				180.4				154.7
Amortization of acquired intangible assets	10.2				10.1				20.4				19.2
Impairment of intangible assets and equipment	—				—				—				4.4
Contingent consideration fair value adjustments	(14.7)				(0.5)				(10.1)				0.4
Restructuring and divestiture charges	1.6				2.9				3.0				3.9
Total operating expenses	289.0				239.4				583.9				548.4
Income from operations	796.8

FAQ

What were Hologic's financial results for Q2 2021?

Hologic reported a revenue increase of 103.4% to $1.54 billion and EPS of $2.38, a 561.1% increase year-over-year.

How did the molecular diagnostics segment perform?

Molecular diagnostics revenue reached $935.3 million, up 390.6%, driven by strong demand for COVID-19 tests.

What is Hologic's guidance for Q3 2021?

Hologic forecasts Q3 revenue between $1,000 million and $1,070 million, with a GAAP EPS guidance of $0.74 to $0.89.

How much cash flow did Hologic generate in Q2 2021?

Hologic generated cash flow from operations of $552.3 million in the second quarter.

What acquisitions did Hologic complete recently?

Hologic completed acquisitions of Diagenode for $153 million, Biotheranostics for $232 million, and SOMATEX for $63 million.